AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Integrator complex subunit 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UL03

UPID:

INT6_HUMAN

Alternative names:

DBI-1; Protein DDX26; Protein deleted in cancer 1

Alternative UPACC:

Q9UL03; Q0P664; Q6PJP4; Q9UFK0; Q9Y5M9

Background:

Integrator complex subunit 6 (Integrator complex subunit 6), also known as DBI-1, Protein DDX26, and Protein deleted in cancer 1, plays a crucial role in the transcription and processing of small nuclear RNAs (snRNA) U1 and U2. It is part of the Integrator complex, associated with RNA polymerase II, and is involved in recruiting cytoplasmic dynein to the nuclear envelope. Its potential tumor suppressor function, highlighted by its ability to suppress tumor cell growth, underscores its biological significance.

Therapeutic significance:

Understanding the role of Integrator complex subunit 6 could open doors to potential therapeutic strategies, especially considering its tumor suppressor capabilities and involvement in fundamental cellular processes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.